PL2178916T3 - Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania - Google Patents
Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowaniaInfo
- Publication number
- PL2178916T3 PL2178916T3 PL08796917T PL08796917T PL2178916T3 PL 2178916 T3 PL2178916 T3 PL 2178916T3 PL 08796917 T PL08796917 T PL 08796917T PL 08796917 T PL08796917 T PL 08796917T PL 2178916 T3 PL2178916 T3 PL 2178916T3
- Authority
- PL
- Poland
- Prior art keywords
- human
- antibodies
- human antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96281107P | 2007-07-31 | 2007-07-31 | |
US6799408P | 2008-03-03 | 2008-03-03 | |
EP08796917.6A EP2178916B1 (en) | 2007-07-31 | 2008-07-31 | Human antibodies to human cd20 and method of using thereof |
PCT/US2008/071709 WO2009018411A1 (en) | 2007-07-31 | 2008-07-31 | Human antibodies to human cd20 and method of using thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2178916T3 true PL2178916T3 (pl) | 2015-08-31 |
Family
ID=40010730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08796917T PL2178916T3 (pl) | 2007-07-31 | 2008-07-31 | Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania |
Country Status (29)
Country | Link |
---|---|
US (3) | US7879984B2 (pl) |
EP (1) | EP2178916B1 (pl) |
JP (1) | JP5588865B2 (pl) |
KR (1) | KR101561020B1 (pl) |
CN (1) | CN101809037B (pl) |
AU (1) | AU2008282152B2 (pl) |
BR (1) | BRPI0813985B1 (pl) |
CA (1) | CA2695199C (pl) |
CO (1) | CO6260105A2 (pl) |
CR (1) | CR11243A (pl) |
DK (1) | DK2178916T3 (pl) |
DO (1) | DOP2010000037A (pl) |
EC (1) | ECSP10010005A (pl) |
ES (1) | ES2527297T3 (pl) |
GT (1) | GT201000026A (pl) |
HK (1) | HK1141811A1 (pl) |
HN (1) | HN2010000202A (pl) |
MA (1) | MA31634B1 (pl) |
ME (1) | ME00973B (pl) |
MX (1) | MX2010000970A (pl) |
MY (1) | MY147651A (pl) |
NI (1) | NI201000016A (pl) |
NZ (1) | NZ583019A (pl) |
PL (1) | PL2178916T3 (pl) |
RU (1) | RU2486205C2 (pl) |
SV (1) | SV2010003468A (pl) |
TN (2) | TN2010000054A1 (pl) |
WO (1) | WO2009018411A1 (pl) |
ZA (1) | ZA201000545B (pl) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
AU2004242614B2 (en) | 2003-05-30 | 2011-09-22 | Merus N.V. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
WO2010132532A1 (en) * | 2009-05-15 | 2010-11-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | B cell surface reactive antibodies |
PT2564695E (pt) | 2009-07-08 | 2015-06-03 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
KR102178064B1 (ko) | 2009-12-21 | 2020-11-12 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 FcγR 마우스 |
JP2014533930A (ja) | 2011-09-19 | 2014-12-18 | カイマブ・リミテッド | 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬 |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
KR102338833B1 (ko) * | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
TW202423993A (zh) * | 2012-11-14 | 2024-06-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
US20140140991A1 (en) * | 2012-11-20 | 2014-05-22 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with bruton's tyrosine kinase |
MX2015009952A (es) | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos. |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用tor激酶抑制劑組合療法以治療癌症之方法 |
US9474757B2 (en) | 2013-04-17 | 2016-10-25 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
US20140314752A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
EP2991651A1 (en) | 2013-05-03 | 2016-03-09 | Celgene Corporation | Methods for treating cancer using combination therapy |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
JP6478989B2 (ja) * | 2013-11-07 | 2019-03-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗cd20抗体とbtk阻害剤とを用いた併用療法 |
TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
DK3179858T3 (da) | 2014-08-13 | 2019-07-22 | Celgene Car Llc | Forme og sammensætninger af en ERK-inhibitor |
GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
EP3699198A1 (en) | 2014-11-17 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
LT3303373T (lt) | 2015-05-30 | 2020-07-10 | Molecular Templates, Inc. | Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės |
NZ737205A (en) | 2015-06-24 | 2024-07-26 | F Hoffmann La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
MY192668A (en) | 2015-10-02 | 2022-08-30 | Hoffmann La Roche | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
RS64588B1 (sr) | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera |
SG11201900373WA (en) * | 2016-07-19 | 2019-02-27 | Ibentrus Inc | Bispecific proteins and methods for preparing same |
WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
EP3551046B1 (en) | 2016-12-07 | 2023-07-19 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
US11524994B2 (en) | 2016-12-19 | 2022-12-13 | Vanderbilt University | Antibodies to human respiratory syncytial virus protein F pre-fusion conformation and methods of use therefor |
CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
CN114075269A (zh) | 2017-07-06 | 2022-02-22 | 菲仕兰坎皮纳荷兰私人有限公司 | 用于制备糖蛋白的细胞培养工艺 |
CN111511762A (zh) | 2017-08-21 | 2020-08-07 | 天演药业公司 | 抗cd137分子及其用途 |
MX2020006639A (es) | 2017-12-22 | 2020-09-14 | Regeneron Pharma | Sistema y metodo para caracterizar las impurezas de un producto farmaceutico. |
AU2019215363A1 (en) | 2018-01-31 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
JP2021514609A (ja) | 2018-02-28 | 2021-06-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ウイルス混入物質を同定するためのシステムおよび方法 |
EP4317959A3 (en) | 2018-03-19 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
MX2021002279A (es) | 2018-08-27 | 2021-05-27 | Regeneron Pharma | Uso de espectroscopia raman en la purificacion corriente abajo. |
WO2020047067A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
JP2021535142A (ja) | 2018-08-31 | 2021-12-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Cd3/c20二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略 |
WO2020061048A1 (en) | 2018-09-17 | 2020-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
CA3115139A1 (en) * | 2018-10-01 | 2020-04-09 | Adicet Bio Inc. | Compositions and methods regarding engineered and non-engineered .gamma..delta.-t cells for treatment of hematological tumors |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
WO2020150491A1 (en) | 2019-01-16 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
EP3969908A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
KR20220066393A (ko) | 2019-09-24 | 2022-05-24 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
MX2022006236A (es) | 2019-11-25 | 2022-06-22 | Regeneron Pharma | Formulaciones de liberacion sostenida con emulsiones no acuosas. |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
EP4085253B1 (en) | 2020-01-21 | 2024-03-13 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
MX2023002417A (es) | 2020-08-31 | 2023-03-22 | Regeneron Pharma | Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina. |
AU2021385363A1 (en) | 2020-11-25 | 2023-06-08 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
CA3205135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
US12031151B2 (en) | 2021-01-20 | 2024-07-09 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
AR125585A1 (es) | 2021-03-03 | 2023-08-02 | Regeneron Pharma | Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas |
AU2022241765A1 (en) | 2021-03-24 | 2023-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof |
WO2022204728A1 (en) | 2021-03-26 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
WO2022256383A1 (en) | 2021-06-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Fc蛋白之高通量及基於質譜之方法 |
EP4405390A1 (en) | 2021-09-20 | 2024-07-31 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
WO2023059800A2 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
IL311248A (en) | 2021-10-07 | 2024-05-01 | Regeneron Pharma | PH meter calibration and repair |
CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
US20240198253A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
WO2024158880A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
US20240248097A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
US20240285762A1 (en) | 2023-02-28 | 2024-08-29 | Juno Therapeutics, Inc. | Cell therapy for treating systemic autoimmune diseases |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
ATE196606T1 (de) * | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
DE69939939D1 (de) * | 1998-08-11 | 2009-01-02 | Idec Pharma Corp | Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern |
US6224866B1 (en) * | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
ES2571230T3 (es) * | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
JP2002544174A (ja) | 1999-05-07 | 2002-12-24 | ジェネンテック・インコーポレーテッド | B細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療 |
ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003208415B2 (en) * | 2002-02-14 | 2009-05-28 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
US20030233797A1 (en) * | 2002-06-25 | 2003-12-25 | Anderson Dean A. | Air handling system including shroud and grille, and method of use |
PL218660B1 (pl) * | 2002-10-17 | 2015-01-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
US6736137B1 (en) | 2003-02-28 | 2004-05-18 | Tmr-A, Llc | Protective hooded respirator with oral-nasal cup breathing interface |
US8084582B2 (en) * | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
KR101412271B1 (ko) | 2003-05-09 | 2014-06-25 | 듀크 유니버시티 | Cd20-특이적 항체 및 이를 이용한 방법 |
AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
DE10334793A1 (de) * | 2003-07-30 | 2005-02-24 | BSH Bosch und Siemens Hausgeräte GmbH | Geschirrspülmaschine |
KR20060132554A (ko) * | 2003-08-29 | 2006-12-21 | 제넨테크, 인크. | 안과 질병의 항-cd20 치료 |
WO2005061542A2 (en) * | 2003-12-19 | 2005-07-07 | Genentech, Inc. | Detection of cd20 in transplant rejection |
US7850962B2 (en) * | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
RU2006142857A (ru) * | 2004-05-05 | 2008-06-10 | Дженентек, Инк. (Us) | Профилактика аутоиммунного заболевания |
CA2568336A1 (en) * | 2004-06-04 | 2005-12-22 | Genentech, Inc. | Method for treating lupus |
BRPI0516297A (pt) * | 2004-10-05 | 2008-09-02 | Genentech Inc | métodos de tratamento de vasculite e artigos de fabricação |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
CN1331888C (zh) * | 2005-03-02 | 2007-08-15 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗人b细胞淋巴瘤的单链双特异性抗体 |
AR053579A1 (es) * | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
KR20070122497A (ko) * | 2005-04-22 | 2007-12-31 | 제넨테크, 인크. | Cd20 항체로 치매 또는 알츠하이머병을 치료하는 방법 |
AU2006252733A1 (en) * | 2005-06-02 | 2006-12-07 | Astrazeneca Ab | Antibodies directed to CD20 and uses thereof |
-
2008
- 2008-07-31 ES ES08796917.6T patent/ES2527297T3/es active Active
- 2008-07-31 RU RU2010107175/10A patent/RU2486205C2/ru active
- 2008-07-31 EP EP08796917.6A patent/EP2178916B1/en active Active
- 2008-07-31 PL PL08796917T patent/PL2178916T3/pl unknown
- 2008-07-31 US US12/183,274 patent/US7879984B2/en active Active
- 2008-07-31 MX MX2010000970A patent/MX2010000970A/es active IP Right Grant
- 2008-07-31 NZ NZ583019A patent/NZ583019A/en unknown
- 2008-07-31 BR BRPI0813985-7A patent/BRPI0813985B1/pt active IP Right Grant
- 2008-07-31 CA CA2695199A patent/CA2695199C/en active Active
- 2008-07-31 KR KR1020107003899A patent/KR101561020B1/ko active IP Right Grant
- 2008-07-31 DK DK08796917.6T patent/DK2178916T3/en active
- 2008-07-31 AU AU2008282152A patent/AU2008282152B2/en active Active
- 2008-07-31 ME MEP-2010-15A patent/ME00973B/me unknown
- 2008-07-31 WO PCT/US2008/071709 patent/WO2009018411A1/en active Application Filing
- 2008-07-31 MY MYPI2010000349A patent/MY147651A/en unknown
- 2008-07-31 JP JP2010520180A patent/JP5588865B2/ja not_active Expired - Fee Related
- 2008-07-31 CN CN200880109581.5A patent/CN101809037B/zh active Active
-
2010
- 2010-01-22 NI NI201000016A patent/NI201000016A/es unknown
- 2010-01-25 ZA ZA2010/00545A patent/ZA201000545B/en unknown
- 2010-01-27 SV SV2010003468A patent/SV2010003468A/es unknown
- 2010-01-27 DO DO2010000037A patent/DOP2010000037A/es unknown
- 2010-01-28 CR CR11243A patent/CR11243A/es unknown
- 2010-01-29 GT GT201000026A patent/GT201000026A/es unknown
- 2010-01-29 TN TNP2010000054A patent/TN2010000054A1/fr unknown
- 2010-01-29 HN HN2010000202A patent/HN2010000202A/es unknown
- 2010-02-01 TN TNP2010000056A patent/TN2010000056A1/fr unknown
- 2010-02-24 MA MA32651A patent/MA31634B1/fr unknown
- 2010-02-26 EC EC2010010005A patent/ECSP10010005A/es unknown
- 2010-02-26 CO CO10023468A patent/CO6260105A2/es active IP Right Grant
- 2010-08-30 HK HK10108217.8A patent/HK1141811A1/xx unknown
- 2010-12-13 US US12/965,956 patent/US8097713B2/en active Active
-
2011
- 2011-12-13 US US13/323,875 patent/US8329181B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1141811A1 (en) | Human antibodies to human cd20 and method of using thereof cd20 | |
IL248723B (en) | Specific antibodies against the bcr complex and methods of using them | |
HUS2100015I1 (hu) | Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére | |
IL198729A0 (en) | Human monoclonal antibodies to btla and methods of use | |
EP2212432A4 (en) | COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES | |
EP2242768A4 (en) | CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION | |
HUE042940T2 (hu) | Anti-FXI antitestek és alkalmazási eljárások | |
EP2427479A4 (en) | ANTIBODIES AND METHODS OF USE THEREOF | |
EP2086583A4 (en) | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USE | |
EP2347038A4 (en) | METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES | |
ZA201005351B (en) | Anti-cd79b antibodies and immunoconjugates and methods of use | |
HK1150839A1 (en) | Compositions and methods of use for therapeutic antibodies | |
IL211623A0 (en) | Anti-notch2 antibodies and methods of use | |
IL215795A0 (en) | Anti-il-17f antibodies and methods of use thereof | |
PT2185719E (pt) | Anticorpos anti-rantes e processos para a sua utilização | |
EP2195025A4 (en) | THERAPEUTIC ANTIBODY PURIFICATION METHOD AND METHOD OF USE | |
IL207030B (en) | Combinations containing glucosylceramide and antibodies against cd3 and their uses |